[{"orgOrder":0,"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Phenylephrine Hydrochloride","moa":"||Adrenergic receptor alpha-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Omeros","amount2":1,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":1,"dosageForm":"Intraocular Solution","sponsorNew":"Omeros \/ Rayner Surgical Group Limited","highestDevelopmentStatusID":"15","companyTruncated":"Omeros \/ Rayner Surgical Group Limited"},{"orgOrder":0,"company":"Eicos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Eicos Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eicos Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eicos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alpha Cognition \/ Inapplicable"},{"orgOrder":0,"company":"Megalabs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"BRAZIL","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"L-Arginine","moa":"Cationic amino acid transporter 3; Antizyme inhibitor 2; Argininosuccinate lyase; Nitric oxide synthase, inducible; High affinity cationic amino acid transporter 1; Arginase-2, mitochondrial; Cationic amino acid transporter 4; Argininosuccinate synthase; Nitric oxide synthase 3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Megalabs","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Megalabs \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Megalabs \/ Inapplicable"},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ iOR Partners"},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.20999999999999999,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Partnership","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Ghassan Aboud Group","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Ghassan Aboud Group"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ US Department of Defense","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ US Department of Defense"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"IRELAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Cultured Keratinocytes Dermal Fibroblasts Murine Collagen","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cultured Epidermal Autograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Avita Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avita Medical \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Acellular Human Extracellular Matrix","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intra-arterial Implant","sponsorNew":"Humacyte \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ Inapplicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Humacyte","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.050000000000000003,"dosageForm":"Intra-arterial Implant","sponsorNew":"Humacyte \/ TD Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Humacyte \/ TD Cowen"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Axolotl Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Axolotl Biologix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Axolotl Biologix \/ Carmell Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Axolotl Biologix \/ Carmell Therapeutics"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Amniotic Membrane","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Film","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lyophilized Human Placental-based Allograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"MiMedx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MiMedx \/ Inapplicable"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"B. Braun Medical \/ Healiva","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Healiva"},{"orgOrder":0,"company":"PolyMedics Innovations","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"PolyMedics Innovations","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"PolyMedics Innovations \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"PolyMedics Innovations \/ MediWound"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Vericel Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vericel Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vericel Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vericel Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Genfa Medica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Genfa Medica \/ MediWound","highestDevelopmentStatusID":"15","companyTruncated":"Genfa Medica \/ MediWound"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioStem Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Dialco Medical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Dialco Medical","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Dialco Medical"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Inapplicable"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Spectral Medical","sponsor":"Paradigm Capital","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Spectral Medical","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Spectral Medical \/ Paradigm Capital","highestDevelopmentStatusID":"15","companyTruncated":"Spectral Medical \/ Paradigm Capital"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProgenaCare Global","sponsor":"Kane Biotech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"ProgenaCare Global","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"ProgenaCare Global \/ Kane Biotech","highestDevelopmentStatusID":"15","companyTruncated":"ProgenaCare Global \/ Kane Biotech"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Salud Pharma","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Edetate Calcium Disodium","moa":"||Metal ion","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Salud Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Salud Pharma"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"||Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Lumenis","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Lumenis","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Lumenis"},{"orgOrder":0,"company":"Abigo Medical AB","sponsor":"Essity","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Dialkylcarbamoylchloride","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Abigo Medical AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abigo Medical AB \/ Essity","highestDevelopmentStatusID":"15","companyTruncated":"Abigo Medical AB \/ Essity"},{"orgOrder":0,"company":"Moleac","sponsor":"PT Ferron Par Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SINGAPORE","productType":"Plant Extract\/Herbal","year":"2024","type":"Partnership","leadProduct":"MLC901","moa":"Cholinesterase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleac \/ PT Ferron Par Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moleac \/ PT Ferron Par Pharmaceuticals"},{"orgOrder":0,"company":"TELA Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nivis Fibrillar Collagen Pack","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"TELA Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TELA Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TELA Bio \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Inapplicable"},{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Funding","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0.20999999999999999,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ BARDA"},{"orgOrder":0,"company":"MediWound","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"ISRAEL","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Bromelain","moa":"Prostaglandin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MediWound \/ Inapplicable"},{"orgOrder":0,"company":"Vaporox","sponsor":"MiMedx","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Human Amnion Membrane Allograft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Vaporox","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Vaporox \/ MIMEDX","highestDevelopmentStatusID":"15","companyTruncated":"Vaporox \/ MIMEDX"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : M22 medical wound dressing (sodium hyaluronate) is a versatile laser treatment system based on Lumenis' medical beauty concept of "30% Laser Treatment and 70% Postoperative care.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 03, 2023

                          Lead Product(s) : Sodium Hyaluronate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Lumenis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bloomage Company Banner

                          02

                          Vaporox

                          Country arrow
                          ESCRS
                          Not Confirmed

                          Vaporox

                          Country arrow
                          ESCRS
                          Not Confirmed

                          Details : MIMEDX invested in Vaporox to co-promote its VHT device alongside their placental allografts, Epifix, delivering a combined wound care solution for chronic ulcers like DFUs, VLUs, and pressure wounds.

                          Product Name : Epifix

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 30, 2025

                          Lead Product(s) : Human Amnion Membrane Allograft

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : MiMedx

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of Symvess (acellular tissue engineered vessel) in the vascular trauma indication.

                          Product Name : Symvess

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 25, 2025

                          Lead Product(s) : Acellular Tissue Engineered Vessel

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : TD Cowen

                          Deal Size : $50.0 million

                          Deal Type : Public Offering

                          blank

                          04

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Symvess is an acellular tissue engineered vessel for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss..

                          Product Name : Symvess

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 26, 2025

                          Lead Product(s) : Acellular Tissue Engineered Vessel

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Symvess is the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed.

                          Product Name : Symvess

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          December 20, 2024

                          Lead Product(s) : Acellular Tissue Engineered Vessel

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Zunveyl (benzgalantamine) is a new generation acetylcholinesterase inhibitor. It is being evaluated for treatment of repetitive mild traumatic brain injury.

                          Product Name : Zunveyl

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : Galantamine Benzoate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                          Product Name : Revyve

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 14, 2024

                          Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Under the partnership, PT Ferron Par Pharmaceuticals will become Moleac's exclusive partner in Indonesia of NeuroAiD II MLC901 which consists of extracts from 9 herbal components.

                          Product Name : NeuroAiD II

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Undisclosed

                          October 21, 2024

                          Lead Product(s) : MLC901

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : PT Ferron Par Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Toraymyxin (Polymyxin B) is a small molecule drug candidate which is shown to inhibit bacterial respiration. It is being evaluated for the treatment of septic shock.

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 04, 2024

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : The proceeds will primarily support Phase III trial for PMX treatment of endotoxemic septic shock, evaluating Toraymyxin (polymyxin B), a therapeutic hemoperfusion device that removes endotoxin.

                          Product Name : Toraymyxin

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 05, 2024

                          Lead Product(s) : Polymyxin B Sulfate

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved FDF

                          Sponsor : Paradigm Capital

                          Deal Size : $6.2 million

                          Deal Type : Financing

                          blank